Friday, September 17, 2021

Latest Posts

Telix Pharmaceuticals: Recruits patients for renal cancer trial

Telix Pharmaceuticals Recruits patients for renal cancer trial

  • Telix Pharmaceuticals (TLX) recruits more than 50 per cent of patients required for its ZIRCON phase three study for imaging renal cancer
  • The trial will treat around 250 renal cancer patients undergoing kidney surgery to determine the sensitivity and specificity of its drug, TLX250-CDx
  • The study has exceeded enrolment expectations despite reduced numbers over the last twelve months due to COVID-19
  • The company Chief Medical Officer Dr Colin Hayward says it’s pleasing to see the trial accelerating and a resumption to normal clinical operating conditions
  • The company says it expects the trial to complete recruitment over the next four to five months, subject to ongoing pandemic conditions
- Advertisement -

Latest Posts

Don't Miss